Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Tango Therapeutics

01/08/2025 15:14

Tango Therapeutics Inc TNGX.OQ TNGX.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The Boston Massachusetts-based  company is expected to report a 66.4% decrease in revenue to $6.679 million from $19.88 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Tango Therapeutics Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Tango Therapeutics Inc is $9.50, about 36.4% above its last closing price of $6.04

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.34
-0.35
-0.36
Missed
-2.9
Dec. 31 2025
-0.33
-0.34
-0.35
Missed
-3.3
Sep. 30 2024
-0.35
-0.37
-0.27
Beat
26.5​
Jun. 30 2024
-0.35
-0.34
-0.24
Beat
30.4
​​Mar. 31 2024
-0.31
-0.31
-0.35
Missed
-11.9
Dec. 31 2023
-0.30
-0.28
-0.32
Missed
-15.2​
Sep. 30 2023
-0.34
-0.34
-0.23
Beat
33.3
Jun. 30 2023
-0.31
-0.34
-0.23
Beat
31.5

This summary was machine generated August 1 at 14:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)